Momenta Phamaceuticals, Inc. (MNTA) Misses Q2 EPS by 2c; Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Product revenue: 23.34M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Product revenue: 23.34M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q2 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $18.99 million.
Momenta Phamaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Momenta Phamaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Phillip Securities Upgrades Indusind Bank Ltd (IIB:IN) to Buy
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
